Business Wire

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), today announced that the Japanese Patent Office has issued the notice of ...
Business Wire

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 ...

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that the Japanese Patent Office has issued the notice of ...